Cargando…

Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis

No head-to-head trials have compared the efficacy and safety of nivolumab (Niv) plus ipilimumab (Ipi) combination therapy (Niv+Ipi) and existing regimens with immunotherapies approved as first-line treatment in patients with programmed cell death ligand 1 (PD-L1)-positive previously untreated advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Koichi, Kishino, Yasunari, Homma, Tetsuya, Kusumoto, Sojiro, Yamaoka, Toshimitsu, Tanaka, Akihiko, Ohmori, Tohru, Ohnishi, Tsukasa, Sagara, Hironori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409193/
https://www.ncbi.nlm.nih.gov/pubmed/32679702
http://dx.doi.org/10.3390/cancers12071905
_version_ 1783568009062776832
author Ando, Koichi
Kishino, Yasunari
Homma, Tetsuya
Kusumoto, Sojiro
Yamaoka, Toshimitsu
Tanaka, Akihiko
Ohmori, Tohru
Ohnishi, Tsukasa
Sagara, Hironori
author_facet Ando, Koichi
Kishino, Yasunari
Homma, Tetsuya
Kusumoto, Sojiro
Yamaoka, Toshimitsu
Tanaka, Akihiko
Ohmori, Tohru
Ohnishi, Tsukasa
Sagara, Hironori
author_sort Ando, Koichi
collection PubMed
description No head-to-head trials have compared the efficacy and safety of nivolumab (Niv) plus ipilimumab (Ipi) combination therapy (Niv+Ipi) and existing regimens with immunotherapies approved as first-line treatment in patients with programmed cell death ligand 1 (PD-L1)-positive previously untreated advanced non-small cell lung cancer (NSCLC). We conducted a network meta-analysis of four relevant Phase Ⅲ trials to compare the efficacy and safety of Niv+Ipi, pembrolizumab (Pem) plus platinum-based chemotherapy (PBC) (Pem+PBC), Pem, Niv, or PBC using Bayesian analysis. The primary efficacy endpoint was progression-free survival (PFS) in patients with advanced NSCLC with PD-L1 expression ≥1%. The primary safety endpoint was the incidence of Grade 3–5 drug-related adverse events (G3–5AEs). Efficacy and safety were ranked using surface under the cumulative ranking curve (SUCRA). With regard to PFS, Niv+Ipi was inferior to Pem+PBC, and superior to Pem, Niv, or PBC alone. SUCRA ranking showed Pem+PBC had the highest efficacy for PFS, followed by Niv+Ipi, Niv, PBC, and Pem. The safety outcome analysis revealed Niv+Ipi was generally well tolerated compared to existing immunotherapy regimens. These results provide clinical information regarding the efficacy and safety of Niv+Ipi and indicate the possibility of the Niv+Ipi combination as a new therapeutic option in PD-L1-positive advanced NSCLC.
format Online
Article
Text
id pubmed-7409193
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74091932020-08-26 Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis Ando, Koichi Kishino, Yasunari Homma, Tetsuya Kusumoto, Sojiro Yamaoka, Toshimitsu Tanaka, Akihiko Ohmori, Tohru Ohnishi, Tsukasa Sagara, Hironori Cancers (Basel) Review No head-to-head trials have compared the efficacy and safety of nivolumab (Niv) plus ipilimumab (Ipi) combination therapy (Niv+Ipi) and existing regimens with immunotherapies approved as first-line treatment in patients with programmed cell death ligand 1 (PD-L1)-positive previously untreated advanced non-small cell lung cancer (NSCLC). We conducted a network meta-analysis of four relevant Phase Ⅲ trials to compare the efficacy and safety of Niv+Ipi, pembrolizumab (Pem) plus platinum-based chemotherapy (PBC) (Pem+PBC), Pem, Niv, or PBC using Bayesian analysis. The primary efficacy endpoint was progression-free survival (PFS) in patients with advanced NSCLC with PD-L1 expression ≥1%. The primary safety endpoint was the incidence of Grade 3–5 drug-related adverse events (G3–5AEs). Efficacy and safety were ranked using surface under the cumulative ranking curve (SUCRA). With regard to PFS, Niv+Ipi was inferior to Pem+PBC, and superior to Pem, Niv, or PBC alone. SUCRA ranking showed Pem+PBC had the highest efficacy for PFS, followed by Niv+Ipi, Niv, PBC, and Pem. The safety outcome analysis revealed Niv+Ipi was generally well tolerated compared to existing immunotherapy regimens. These results provide clinical information regarding the efficacy and safety of Niv+Ipi and indicate the possibility of the Niv+Ipi combination as a new therapeutic option in PD-L1-positive advanced NSCLC. MDPI 2020-07-15 /pmc/articles/PMC7409193/ /pubmed/32679702 http://dx.doi.org/10.3390/cancers12071905 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ando, Koichi
Kishino, Yasunari
Homma, Tetsuya
Kusumoto, Sojiro
Yamaoka, Toshimitsu
Tanaka, Akihiko
Ohmori, Tohru
Ohnishi, Tsukasa
Sagara, Hironori
Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
title Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
title_full Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
title_fullStr Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
title_full_unstemmed Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
title_short Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
title_sort nivolumab plus ipilimumab versus existing immunotherapies in patients with pd-l1-positive advanced non-small cell lung cancer: a systematic review and network meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409193/
https://www.ncbi.nlm.nih.gov/pubmed/32679702
http://dx.doi.org/10.3390/cancers12071905
work_keys_str_mv AT andokoichi nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis
AT kishinoyasunari nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis
AT hommatetsuya nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis
AT kusumotosojiro nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis
AT yamaokatoshimitsu nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis
AT tanakaakihiko nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis
AT ohmoritohru nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis
AT ohnishitsukasa nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis
AT sagarahironori nivolumabplusipilimumabversusexistingimmunotherapiesinpatientswithpdl1positiveadvancednonsmallcelllungcancerasystematicreviewandnetworkmetaanalysis